See the published version of this preprint at BMC Veterinary Research.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Hee-Myung Park
Corresponding Author
ORCiD: https://orcid.org/0000-0002-7254-9524
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Fluoroquinolone agents, such as enrofloxacin and marbofloxacin, are commonly used in pseudomonal infection in veterinary medicine. However, the resistance rate to fluoroquinolone is rapidly increasing according to multiple studies in various countries. The point mutation in quinolone resistance determining region (QRDR) is closely related to increased fluoroquinolone resistance of Pseudomonas aeruginosa . The aim of this study was to investigate current antimicrobial susceptibility and fluoroquinolone resistance in Pseudomonas aeruginosa strains isolated from dogs. The presence of the point mutations in the QRDR was confirmed by gyrA and parC polymerase chain reaction and nucleotide sequencing analysis.
Results
A total of 84 nonduplicated P. aeruginosa isolates were obtained from 228 healthy dogs (healthy group) and 260 dogs with clinical signs (infected group). From these, 38 isolates from the healthy group were detected in several samples, whereas 46 isolates from the infected group were mostly obtained from dogs’ ears with otitis externa (41/260, 15.8%). All isolates were resistant to nalidixic acid, while some were also resistant to enrofloxacin (23/84, 27.4%), marbofloxacin (17/84, 20.2%), levofloxacin (12/84, 14.3%), or ciprofloxacin (11/84, 13.1%). Enrofloxacin resistance was significantly higher in strains from the infected group than that of the healthy group ( p <0.05). Among the 23 fluoroquinolone-resistant isolates, 8 and 4 different mutations were detected in the gyrA and parC genes, respectively. Mutations in gyrA were significantly common in the infected group ( p <0.05). Hotspots for the gyrA and parC mutations were Thr83 (34.8%, 8/23) and Pro116 (91.3%, 21/23), respectively. Double and triple mutations were also found in 5 of the isolates.
Conclusion
Novel mutations in the gyrA and parC genes were first found in P. aeruginosa isolates from companion dogs in South Korea. These findings suggest that it is important to know the prudent use of fluoroquinolone antibiotics in canine pseudomonas infection treatment.
Keywords
companion dogs, P. aeruginosa, novel mutations, gyrA, parC
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Veterinary Research.
No community comments so far
Editorial decision: Accept
On 25 Mar, 2020
Editor assigned
On 24 Mar, 2020
Submission checks complete
On 23 Mar, 2020
Editor invited
On 23 Mar, 2020
No comments provided
Submission checks complete
On 18 Mar, 2020
Editorial decision: Minor revision
On 18 Mar, 2020
No comments provided
Editorial decision: Minor revision
On 10 Mar, 2020
Editor assigned
On 26 Feb, 2020
Submission checks complete
On 25 Feb, 2020
Editor invited
On 25 Feb, 2020
No comments provided
Editorial decision: Major revision
On 30 Jan, 2020
Review #1 received
Received 20 Jan, 2020
Review #2 received
Received 20 Jan, 2020
Editor assigned
On 17 Jan, 2020
Reviewers invited
Invitations sent on 17 Jan, 2020
Reviewer #1 agreed
On 17 Jan, 2020
Reviewer #2 agreed
On 17 Jan, 2020
Submission checks complete
On 16 Jan, 2020
Editor invited
On 16 Jan, 2020
Version 1
Posted 20 Aug, 2019
No comments provided
Editorial decision: Major revision
On 18 Dec, 2019
Review #3 received
Received 10 Dec, 2019
Reviewer #3 agreed
On 29 Nov, 2019
Review #2 received
Received 20 Nov, 2019
Reviewer #2 agreed
On 17 Nov, 2019
Review #1 received
Received 09 Sep, 2019
Reviewer #1 agreed
On 02 Sep, 2019
Reviewers invited
Invitations sent on 01 Sep, 2019
Editor assigned
On 20 Aug, 2019
Submission checks complete
On 16 Aug, 2019
Editor invited
On 16 Aug, 2019
First submitted
On 11 Aug, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Small Animal Medicine
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Veterinary Research.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Hee-Myung Park
Corresponding Author
ORCiD: https://orcid.org/0000-0002-7254-9524
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Veterinary Research.
No community comments so far
Editorial decision: Accept
On 25 Mar, 2020
Editor assigned
On 24 Mar, 2020
Submission checks complete
On 23 Mar, 2020
Editor invited
On 23 Mar, 2020
No comments provided
Submission checks complete
On 18 Mar, 2020
Editorial decision: Minor revision
On 18 Mar, 2020
No comments provided
Editorial decision: Minor revision
On 10 Mar, 2020
Editor assigned
On 26 Feb, 2020
Submission checks complete
On 25 Feb, 2020
Editor invited
On 25 Feb, 2020
No comments provided
Editorial decision: Major revision
On 30 Jan, 2020
Review #1 received
Received 20 Jan, 2020
Review #2 received
Received 20 Jan, 2020
Editor assigned
On 17 Jan, 2020
Reviewers invited
Invitations sent on 17 Jan, 2020
Reviewer #1 agreed
On 17 Jan, 2020
Reviewer #2 agreed
On 17 Jan, 2020
Submission checks complete
On 16 Jan, 2020
Editor invited
On 16 Jan, 2020
Version 1
Posted 20 Aug, 2019
No comments provided
Editorial decision: Major revision
On 18 Dec, 2019
Review #3 received
Received 10 Dec, 2019
Reviewer #3 agreed
On 29 Nov, 2019
Review #2 received
Received 20 Nov, 2019
Reviewer #2 agreed
On 17 Nov, 2019
Review #1 received
Received 09 Sep, 2019
Reviewer #1 agreed
On 02 Sep, 2019
Reviewers invited
Invitations sent on 01 Sep, 2019
Editor assigned
On 20 Aug, 2019
Submission checks complete
On 16 Aug, 2019
Editor invited
On 16 Aug, 2019
First submitted
On 11 Aug, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Small Animal Medicine
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Veterinary Research.
Background
Fluoroquinolone agents, such as enrofloxacin and marbofloxacin, are commonly used in pseudomonal infection in veterinary medicine. However, the resistance rate to fluoroquinolone is rapidly increasing according to multiple studies in various countries. The point mutation in quinolone resistance determining region (QRDR) is closely related to increased fluoroquinolone resistance of Pseudomonas aeruginosa . The aim of this study was to investigate current antimicrobial susceptibility and fluoroquinolone resistance in Pseudomonas aeruginosa strains isolated from dogs. The presence of the point mutations in the QRDR was confirmed by gyrA and parC polymerase chain reaction and nucleotide sequencing analysis.
Results
A total of 84 nonduplicated P. aeruginosa isolates were obtained from 228 healthy dogs (healthy group) and 260 dogs with clinical signs (infected group). From these, 38 isolates from the healthy group were detected in several samples, whereas 46 isolates from the infected group were mostly obtained from dogs’ ears with otitis externa (41/260, 15.8%). All isolates were resistant to nalidixic acid, while some were also resistant to enrofloxacin (23/84, 27.4%), marbofloxacin (17/84, 20.2%), levofloxacin (12/84, 14.3%), or ciprofloxacin (11/84, 13.1%). Enrofloxacin resistance was significantly higher in strains from the infected group than that of the healthy group ( p <0.05). Among the 23 fluoroquinolone-resistant isolates, 8 and 4 different mutations were detected in the gyrA and parC genes, respectively. Mutations in gyrA were significantly common in the infected group ( p <0.05). Hotspots for the gyrA and parC mutations were Thr83 (34.8%, 8/23) and Pro116 (91.3%, 21/23), respectively. Double and triple mutations were also found in 5 of the isolates.
Conclusion
Novel mutations in the gyrA and parC genes were first found in P. aeruginosa isolates from companion dogs in South Korea. These findings suggest that it is important to know the prudent use of fluoroquinolone antibiotics in canine pseudomonas infection treatment.
Loading...